JPWO2022093983A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022093983A5 JPWO2022093983A5 JP2023525980A JP2023525980A JPWO2022093983A5 JP WO2022093983 A5 JPWO2022093983 A5 JP WO2022093983A5 JP 2023525980 A JP2023525980 A JP 2023525980A JP 2023525980 A JP2023525980 A JP 2023525980A JP WO2022093983 A5 JPWO2022093983 A5 JP WO2022093983A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- cells
- hematopoietic
- gemtuzumab ozogamicin
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 29
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims 20
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 10
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 230000003394 haemopoietic effect Effects 0.000 claims 5
- 230000003211 malignant effect Effects 0.000 claims 5
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 claims 4
- 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102000054766 genetic haplotypes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 230000009033 hematopoietic malignancy Effects 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000034951 Genetic Translocation Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 2
- 208000007660 Residual Neoplasm Diseases 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000002435 cytoreductive effect Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
- 206010068051 Chimerism Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 206010062489 Leukaemia recurrent Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 101710160107 Outer membrane protein A Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
- 230000001494 anti-thymocyte effect Effects 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 229960002092 busulfan Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 238000009093 first-line therapy Methods 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 238000010362 genome editing Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 230000000877 morphologic effect Effects 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 238000011285 therapeutic regimen Methods 0.000 claims 1
- 229960001196 thiotepa Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063106136P | 2020-10-27 | 2020-10-27 | |
| US63/106,136 | 2020-10-27 | ||
| US202163165950P | 2021-03-25 | 2021-03-25 | |
| US63/165,950 | 2021-03-25 | ||
| PCT/US2021/056885 WO2022093983A1 (en) | 2020-10-27 | 2021-10-27 | Compositions and methods for treating hematopoietic malignancy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023548111A JP2023548111A (ja) | 2023-11-15 |
| JP2023548111A5 JP2023548111A5 (https=) | 2024-11-05 |
| JPWO2022093983A5 true JPWO2022093983A5 (https=) | 2024-11-05 |
Family
ID=78820515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023525980A Pending JP2023548111A (ja) | 2020-10-27 | 2021-10-27 | 造血悪性腫瘍を治療するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240000846A1 (https=) |
| EP (1) | EP4236970A1 (https=) |
| JP (1) | JP2023548111A (https=) |
| KR (1) | KR20230097089A (https=) |
| AU (1) | AU2021372482A1 (https=) |
| CA (1) | CA3199623A1 (https=) |
| IL (1) | IL302252A (https=) |
| WO (1) | WO2022093983A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024168312A1 (en) * | 2023-02-09 | 2024-08-15 | Vor Biopharma Inc. | Methods for treating hematopoietic malignancy |
| CN116949097B (zh) * | 2023-09-20 | 2023-12-12 | 江苏集萃药康生物科技股份有限公司 | 一种sema4d人源化小鼠模型的构建方法及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5733001A (en) | 1996-11-19 | 1998-03-31 | Roberts; Clifford D. | Seat cover retainer apparatus and method of using same |
| AU2002348178A1 (en) * | 2002-11-06 | 2004-06-03 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| EP2211870A1 (en) * | 2007-11-01 | 2010-08-04 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| EP3556858A3 (en) | 2014-04-09 | 2020-01-22 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating cystic fibrosis |
| US10900034B2 (en) | 2014-12-03 | 2021-01-26 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
| EP3280803B1 (en) | 2015-04-06 | 2021-05-26 | The Board of Trustees of the Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
| JP7109784B2 (ja) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したＣａｓ９蛋白質 |
| WO2017177011A1 (en) * | 2016-04-06 | 2017-10-12 | University Of Florida Research Foundataion, Inc. | Biomarkers for anti-leukemic therapy |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| AU2017388753A1 (en) | 2016-12-30 | 2019-07-11 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| SG11201907870VA (en) * | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| US11718659B2 (en) * | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
| MX2021008490A (es) * | 2019-01-16 | 2021-09-28 | Univ Columbia | Composiciones y metodos para la inhibicion de antigenos con especificidad de linaje. |
-
2021
- 2021-10-27 CA CA3199623A patent/CA3199623A1/en active Pending
- 2021-10-27 US US18/033,461 patent/US20240000846A1/en active Pending
- 2021-10-27 AU AU2021372482A patent/AU2021372482A1/en active Pending
- 2021-10-27 WO PCT/US2021/056885 patent/WO2022093983A1/en not_active Ceased
- 2021-10-27 KR KR1020237017584A patent/KR20230097089A/ko active Pending
- 2021-10-27 IL IL302252A patent/IL302252A/en unknown
- 2021-10-27 EP EP21819271.4A patent/EP4236970A1/en active Pending
- 2021-10-27 JP JP2023525980A patent/JP2023548111A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Granot et al. | History of hematopoietic cell transplantation: challenges and progress | |
| Tricot et al. | Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients | |
| Remberger et al. | Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study | |
| Parker et al. | Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced‐intensity conditioning compared with standard preparative regimens | |
| Barrett et al. | Bone marrow transplantation for acute lymphoblastic leukaemia | |
| Liu et al. | Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia | |
| Craddock et al. | Circulating stem cells in mice treated with cyclophosphamide | |
| Al-Shaibani et al. | Comparison of outcomes after second allogeneic hematopoietic cell transplantation versus donor lymphocyte infusion in allogeneic hematopoietic cell transplant patients | |
| Yang et al. | Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia | |
| CN119317442A (zh) | 用于治疗癌症的方法中的cd19 car nk细胞 | |
| Georges et al. | Stem cell transplantation for aplastic anemia | |
| Good et al. | Bone marrow transplantation—an expanding approach to treatment of many diseases | |
| Yang et al. | Aplastic anemia preconditioned with fludarabine, cyclophosphamide, and anti-thymocyte globulin | |
| Troussard et al. | Allogeneic bone marrow transplantation in adults with Burkitt's lymphoma or acute lymphoblastic leukemia in first complete remission. | |
| Lupu et al. | Five decades of progress in haematopoietic cell transplantation based on the preclinical canine model | |
| JPWO2022093983A5 (https=) | ||
| Baron et al. | Current roles for allogeneic hematopoietic cell transplantation following nonmyeloablative or reduced-intensity conditioning. | |
| Chattopadhyay et al. | Fludarabine-based low-intensity conditioning for Fanconi anemia is associated with good outcomes in aplastic anemia but not in MDS-a single-center experience | |
| Mei et al. | How to approach a Hodgkin lymphoma patient with relapse after autologous SCT: allogeneic SCT | |
| Labar | Hematopoietic stem cell transplantation in Zagreb: the first 40 years | |
| Haran-Ghera | Host resistance against isotransplantation of lymphomas induced by the radiation leukaemia virus | |
| Devine et al. | Hematopoietic cell transplantation in the treatment of leukemia | |
| Attal et al. | Autologous peripheral blood progenitor cell transplantation for multiple myeloma | |
| Pisani et al. | Management of high-risk myelodysplastic syndromes | |
| Mariani et al. | Alteration of skin in Gross leukemia. II. Kinetic, preleukemic, and irradiation studies |